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                                             Abstract 
Non-small cell lung cancer (NSCLC) comprises more than 75% of lung cancer cases and is 
usually diagnosed in advanced stages. Lung cancer is the leading cause of cancer death among 
all solid tumours and the second most common malignancy globally. The prognosis of 
NSCLC patients with brain metastases (BM) is poor with a median overall survival of 4–11 
weeks in untreated patients and 4–15 months in treated patients. Approximately 45% of 
patients with non-oncogenic driven NSCLC and 70% of patients with EML4-ALK 
rearrangements or EGFR mutations will be diagnosed with BM during the course of the 
disease. The incidence of BM appears to be increasing mostly owing to improvements in 
diagnostic imaging and in survival associated with more effective systemic therapies. The 
main purpose of this thesis is to identify clinical and molecular biomarkers for BM of 
NSCLC, as well as to explore the molecular diversity between CNS metastases and primary 
NSCLC. 
Paper I was a single institution cohort study including brain metastasized lung cancer patients 
who received Whole Brain Radiotherapy (WBRT) at Karolinska University Hospital, 
Stockholm, Sweden. The aim of this trial was to find prognostic factors that can influence OS 
in lung cancer patients with BM treated with WBRT, in order to identify which patients will 
live long enough to experience the palliative benefit of WBRT, regarding disease control in 
the CNS. This study provided additional information on the selection of BM NSCLC patients 
who should receive WBRT by combining RPA and GRA prognostic indexes. 
In paper II we analysed a total of 43 tissue samples from NSCLC patients for systematic 
mRNA expression; 13 primary tumours and 30 brain metastases. The material was obtained 
from 25 patients, of which 13 underwent surgery of the primary tumour. The paired samples 
were 26 (13 patients with both available lung and brain tissue samples). A unique gene 
downregulation pattern in brain metastases compared with primary tumours was observed. 
This finding may explain the lower intracranial efficacy of systemic therapy, especially 
immunotherapy, in the brain metastatic setting. 
In paper III the validity of Lung-molGPA index in an ALK-positive lung cancer cohort with 
BM (n= 44) was explored, and a new prognostic scoring system, the ALK-BPI score, which 
can be easily applicable in clinical practice was proposed. PS, sex and BM at diagnosis, were 
used as prognostic variables in ALK-BPI. 
The aim of paper IV - a retrospective cohort study consisting of 304 patients with surgically 
removed NSCLC- was to investigate whether high expression of NRF2 or TrxR1 in early 
stage NSCLC is predictive for relapse in CNS or other organs. High expression of NRF2 in 
cytokeratine positive cells in the whole tissue core compartment was correlated with higher 
risk for CNS relapse. This is to our knowledge the first study to report a predictive biomarker 
for CNS relapse in early stage NSCLC. 
In summary, this thesis expands the knowledge regarding the molecular diversity between 
CNS metastases and primary NSCLC, and proposes new clinical and molecular biomarkers 
for BM of NSCLC. 
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1 Background     
                  
     
1.1 Introduction-Epidemiology 
Brain metastasis (BM) from solid tumours is more frequent than primary brain tumours. 
Dissemination in the central nervous system (CNS) occurs in up to 44% of patients with 
advanced non-small cell lung cancer (NSCLC), particularly in patients with adenocarcinoma 
[1]. Brain metastases are associated with a poor prognosis, with a median overall survival of 4–
11 weeks in untreated patients and 4–15 months in treated patients [2, 3] . Especially patients 
with leptomeningeal carcinomatosis have a worse prognosis and therapeutic options are limited 
without any convincing palliative benefit in published studies; median overall survival not 
exceeding 2-3 months in treated patients and 4-6 weeks in untreated patients [4-6]. The blood–
brain barrier is a physiologic obstruction to the delivery of systemic therapy to the central 
nervous system (CNS) and may contribute to treatment resistance.  
The overall incidence of BM in advanced NSCLC increases to about 45% in the general patient 
population and up to around 70% of patients with EML4-ALK rearrangements or EGFR 
mutations will be diagnosed with BM during the course of the disease [1, 7-10]. The increasing 
incidence of BM is driven by the improvements in diagnostic imaging and survival due to more 
effective systemic therapies in the recent years [11]. 
 
1.2 Prognostic scores 
Several prognostic scoring systems have been developed for patients with brain metastatic lung 
cancer. Recursive Partitioning Analysis (RPA) and Graded Prognostic Assessment (GPA) are 
the most widely used and validated scoring systems [12-14]. The RPA classification system 
was first published in 1997 and divided patients with brain metastases in three prognostic 
classes according to age, control of primary tumour, performance status measured according to 
Karnofsky Performance Scale (KPS) and the presence of extracranial disease. RPA was the first 
clinically important scoring system for NSCLC patients with BM [13, 14]. Thereafter, several 
prognostic scoring systems have been proposed for patients receiving WBRT or SRS (or both), 
adding parameters such as extracranial tumour control, interval between tumour diagnosis and 
WBRT start, number and volume of brain metastases, in relation to neurological outcomes and 
survival. [15-20]. The initial GPA-score was published in 2008 and has thereafter been 
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validated in other cohorts [21, 22]. The variables that proved to be significant in the GPA 
scoring system were Karnofsky performance status, age, presence of extracranial metastases, 
and number of brain metastases.  
The disease-specific (DS) GPA, published in 2012, does not differ from the original publication 
regarding NSCLC patients with BM [23]. GPA was updated even regarding NSCLC patients 
with EGFR or ALK positive tumours. This lung-molGPA scoring system was published in 
2016, based on 2,186 patients diagnosed with NSCLC and BM from 2006 to 2014 [24]. 
Sperduto et al. incorporated molecular characteristics (EGFR and/or ALK alterations) to 
previous significant variables, albeit lung-mol GPA has not yet been validated in large cohorts 
with only ALK- or EGFR-positive tumours [25]. A Chinese study published in 2017 failed to 
validate Lung-molGPA as a prognostic score [26]. 
 
 1.3 Local Treatment of NSCLC with brain metastases 
The majority of clinical trials evaluating the efficacy of surgery, whole brain radiotherapy 
(WBRT) and stereotactic radiosurgery (SRS) in metastatic brain tumours are not performed in 
lung cancer patients only. They consist of various primary tumours with different clinical 
courses and different metastatic burden. Therefore, it is difficult to draw safe conclusions for 
NSCLC, but on the other hand lung cancer patients are overrepresented in most of these trials 
as lung cancer has the highest frequency of brain metastases, as mentioned above [1, 27]. This 
is the reason for the wide application of the conclusions of such studies in lung cancer patients. 
1.3.1 Surgery: in 2010, the first evidence-based compendium for the treatment of patients with 
brain metastases published a level 1 recommendation for surgical resection combined with 
radiation therapy to prolong life in relatively young patients with good functional status and a 
newly diagnosed solitary brain metastasis [28]. Prior to this formal guidance on the utility of 
surgery in patients with brain metastases, the benefits of this therapeutic option had been 
established in other studies [29, 30].  
1.3.2 Whole-brain radiation therapy (WBRT): WBRT has been the standard-of-care for 
multiple NSCLC brain metastases for many years [31]. On the basis of a recursive partitioning 
analysis (RPA) of data from patients treated between 1979 and 1993 on previous RTOG 
protocols, even patients with brain metastasis who had the best prognosis had a median survival 
of only 7 months after WBRT alone[13]. The British Quartz trial, which included mostly RPA 
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class II and III patients, has shown no survival benefit, no difference in quality adjusted life 
years and no difference in corticosteroid use for patients with brain metastases from NSCLC 
who received WBRT, compared to dexamethasone and best supportive care only [32]. WBRT 
has not been shown to prolong survival in patients with leptomeningeal disease and its role in 
symptom palliation is controversial [33-35]. However, with improvements in systemic 
therapies for a variety of cancers, patient survival has now increased, even among those with 
metastatic disease [36]. In this context, WBRT alone is increasingly found to be inadequate in 
the long-term control of brain metastasis. In addition, with these improved outcomes many 
patients for whom control of brain disease is achieved with WBRT are surviving to experience 
the considerable neurocognitive sequelae and declines in quality-of-life that are associated with 
this treatment [37]. The classic neurocognitive toxicity associated with WBRT in adults is a 
moderate-to-severe dementia that occurs several months to years after treatment. De Angelis 
et al [38] observed a 2–5% incidence of severe dementia in populations of patients who had 
undergone WBRT (with or without surgical resection) for brain metastases, although these 
authors estimated that a markedly higher incidence of dementia would have been found if less 
severe cases of neurological decline were also included. An early neurocognitive decline, 
predominantly in verbal memory, occurring 1–4 months after WBRT has also been described 
[39].  
1.3.3 WBRT and/or SRS: In order to avoid toxicity issues related to WBRT, SRS alone has 
been advocated in patients with better prognosis and a limited number of metastases [40, 41]. 
Two randomized studies [42, 43] have demonstrated that such patients (populations with one 
to three or four lesions) receiving SRS alone had a similar survival to patients who received 
WBRT and SRS. A series of meta-analyses of randomized controlled studies that investigated 
WBRT and SRS confirmed that WBRT did not enhance overall survival in patients with a 
limited number of brain metastases (up to four) [44]; however, reduced local and distant control 
of brain metastasis was observed after treatment with SRS alone compared with WBRT and 
SRS [44]. Indeed, as might be expected, patients treated with SRS alone do experience 
increased recurrences of metastasis elsewhere in the brain, but salvage with either repeat SRS 
or WBRT results in survival comparable to initial treatment with WBRT and SRS [44]. With 
respect to neurocognitive and performance outcomes, studies have demonstrated a considerable 
improvement in the preservation of neurocognitive function and performance status in patients 
treated with SRS alone compared with WBRT and SRS [43-46]. A randomized study by the 
European Organisation for Research and Treatment of Cancer (EORTC) further supports the 
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validity of using local therapy only (SRS or surgery) versus local therapy combined with WBRT 
in patients with one to three brain metastases, demonstrating no improvement in overall survival 
with the addition of WBRT [47]. Of note, patients in the WBRT arm of the EORTC trial scored 
markedly worse on health-related quality-of-life measures, both at early and late time points 
after treatment [42]. However, another randomized trial showed an overall survival benefit in 
univariate analysis for patients with one to three brain metastases who received WBRT and 
SRS compared to single WBRT, but this result was not validated in the multivariate analysis, 
and in a subgroup analysis the OS benefit was restricted to patients with single metastasis [48]. 
In the same study, Karnofsky Performance Status (KPS) at 6 months and local control were 
improved in the combined treatment arm, compared to single WBRT. A Cochrane meta-
analysis regarding radiotherapy use for the treatment of multiple brain metastases has shown 
no difference in OS with combined SRS and WBRT versus SRS, and no OS difference with 
different fractionation and dosing of WBRT [49]. This meta-analysis showed better local 
control with combined WBRT and SRS and less side effects with single SRS. Pooled results 
from three randomized trials [43, 45, 50] (comprising a total of 364 patients) have revealed an 
apparent survival advantage in younger patients (< 50 years old) treated with SRS alone 
compared with WBRT and SRS [51]; the reason for this surprising result is not entirely clear at 
this time. At present, the use of SRS alone in patients with more than three metastatic lesions 
in the brain can be considered, although routine use of this approach in such instances will 
require validation in additional randomized controlled trials [52].  
1.3.4 Adjuvant WBRT and/or SRS. In the adjuvant setting SRS or WBRT can increase local 
control rates with the latter having a greater impact on distant CNS recurrence-free survival, as 
shown in a meta-analysis [53]. This benefit in distant recurrence-free survival shown with 
WBRT is related to higher toxicity rates in the CNS, as mentioned above. A randomized trial 
by Patchell et al has shown better local and distant control in the CNS, as well as lower risk of 
death due to CNS recurrence for patients receiving adjuvant WBRT compared to observation 
only [54]. Up to date, studies of adjuvant RT in the CNS have been underpowered regarding 
OS and have not shown any such benefit.  
 
1.4 Systemic Therapy of NSCLC with Brain Metastases 
1.4.1 Chemotherapy: Early studies of traditional systemic chemotherapy agents showed 
clinical benefit in CNS metastasized NSCLC, especially in asymptomatic patients,  often 
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enabling avoidance of local intervention such as surgery and radiation [55, 56].  Similarly, 
salvage therapy with cytotoxic chemotherapeutic agents owing to progression of disease after 
radiation therapy or surgical resection was also associated with clinical benefit, albeit modest 
[56]. Combination chemotherapy regimens, such as carboplatin with paclitaxel, cisplatin with 
vinorelbine, or carboplatin with etoposide, given in first line, have been shown to induce 
objectively measured responses of metastatic brain lesions in approximately 20–45% of patients 
with lung cancer, allowing delay of WBRT [57-59]. There is insufficient data to suggest the use 
of temozolomide monotherapy in the treatment of brain metastatic NSCLC, although some 
effect has been reported with dose-dense temozolomide in a small multicentre phase II trial 
[60], and also some activity has been observed against a variety of brain metastasized tumours 
[61].   
In two phase III trials, examining concomitant topotecan or carboplatin with WBRT for brain 
metastasized lung cancer patients, no survival advantage was observed [62, 63]. A recent meta-
analysis on the effect of concomitant temozolomide given with WBRT showed a modest 
increase in objective response rate (ORR), but failed to show any OS or PFS benefit [64]. 
1.4.2 Epidermal Growth Factor Receptor (EGFR) inhibitor therapy: EGFR-mutations are 
mainly detected in exons 18–21 of the EGFR gene encoding for the tyrosine kinase (TK) 
domain, and particularly the binding sites of EGFR tyrosine kinase inhibitors (TKIs) [65-67]. 
In more than 85% of cases, EGFR mutations are exon 19 deletions or the L858R point mutation 
in exon 21 [65, 67, 68]. These mutations are almost exclusively found in non-squamous 
NSCLCs, particularly papillary and lepidic adenocarcinoma [66]. In NSCLC, EGFR mutations 
are considered mutually exclusive from other molecular alterations, such as K-Ras and HER2 
mutations or ALK gene rearrangements, although coexistence of two or more driver mutations 
in the same patient can occasionally occur [69]. In NSCLC, EGFR mutations were reported in 
5–10% of Whites, in 30% of White never-smokers, and more than 60% of Asian never-smokers. 
EGFR mutations are more common in women (20–62%) than men (1–19%) [66, 69]. 
First-generation EGFR TKIs erlotinib and gefitinib, second-generation afatinib and 
dacomitinib, and third- generation osimertinib, have been approved for the treatment of EGFR-
mutated NSCLC in the first and later lines; for osimertinib in the second-line setting for tumours 
which develop resistance to first-line TKIs through the EGFR T790M mutation [70-81]. Orally 
administered gefitinib successfully controlled established intracerebral tumours derived from 
EGFR-expressing epidermoid cancers [82]. Gefitinib has also shown activity in NSCLC 
patients with brain metastases with unknown EGFR mutational status, with CNS disease control 
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rates ranging from 27% to 100% [83, 84]. However, clinical evidence for efficacy of these 
agents in tumours affecting the CNS comes mainly from subgroup analyses of randomized 
clinical trials, small prospective, retrospective observational studies and case series [82, 85-91] 
(Table 1). In general, first generation EGFR-targeting agents have a low capacity to penetrate 
into the cerebrospinal fluid (CSF), although erlotinib achieved relatively higher level of CNS 
penetration, which might in part explain the improved control of brain metastasis that has been 
observed with erlotinib treatment, even in patients previously treated with gefitinib (Table 1) 
[92]. Furthermore, the use of EGFR TKIs rather than chemotherapy as frontline therapy of 
EGFR-mutant lung cancer also reduced the cumulative incidence of progressive CNS 
metastasis (HR=0.56; 95% CI=0.34–0.94): 6-month, 12-month and 24-month cumulative risk 
of CNS metastasis was 1%, 6%, and 21%, respectively, in patients treated with EGFR-targeted 
agents compared with 7%, 19% and 32%, respectively, in those who received chemotherapy 
(P=0.026) [93]. In the FLAURA study, where osimertinib was compared to erlotinib or gefitinib 
in the first-line setting (N=556), patients with neurologically stable BM were allowed. In this 
trial, events of CNS progression were observed in 17 patients (6%) in the osimertinib group and 
42 (15%) in the standard EGFR TKI group, irrespective of BM status at randomization [81]. A 
subgroup analysis of the FLAURA study done in 128 patients with BM at baseline showed that 
for osimertinib-treated patients, median CNS progression-free survival was not reached (95% 
CI, 16.5 months to not calculable) compared to 13.9 months (95% CI, 8.3 months to not 
calculable) with standard EGFR TKIs (HR=0.48; 95% CI, 0.26 to 0.86). CNS ORRs were 91% 
and 68%, respectively, in patients with one measurable CNS lesion (odds ratio=4.6; 95%CI, 
0.9 to 34.9; P=.066) and 66% and 43%, respectively, in patients with measurable and/or non-
measurable CNS lesions (odds ratio=2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib 
or standard EGFR-TKIs [94].   
Other prospective studies investigating the efficacy of first-generation EGFR TKIs in the 
treatment of brain metastasis have been mostly non-randomized single-arm phase II studies. 
One such study evaluated the role of erlotinib as a radiosensitizing agent in 40 patients with 
brain metastasis arising from lung cancer irrespective of the EGFR status of the tumour, and 
demonstrated the safety of this approach and a disease control rate of >80% (Table 1) [95]. 
Likewise, an EGFR mutation was detected in 53% of tumours with tissue available for testing, 
which is a high proportion when compared with the expected rate of EGFR mutations in 
Western populations of patients with lung cancer, suggesting that EGFR mutations can confer 
increased propensity for brain involvement. In the RTOG 0320 study, combination treatment 
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with WBRT, SRS and erlotinib/or temozolomide was compared to WBRT and SRS, showing 
that the combination treatment with TKI/or temozolomide and local RT had worse OS and 
higher toxicity [96]. The RTOG 0320 study was terminated prematurely due to poor accrual of 
patients and the patients included were not tested for EGFR mutation status, making it difficult 
to draw any clinically important conclusions.  
In a study with NSCLC progressing after at least one line of chemotherapy and one line of 
EGFR TKI, patients received afatinib [97]. Afatinib appears to penetrate into the CNS with 
concentrations high enough to have clinical effect on CNS metastases and proved to be an 
effective treatment for heavily pre-treated patients with EGFR-mutated or EGFR TKI-sensitive 
NSCLC and CNS metastasis. Time to treatment failure (TTF) did not differ in patients with or 
without CNS metastases and over 70% of the patients with CNS metastases had either partial 
response (PR) or stable disease (SD), while 76% of the patients did not develop any new 
metastases. However, this study had many limitations, especially considering that the majority 
of patients had received WBRT before therapy with afatinib [97]. Afatinib has also shown a 
trend towards longer PFS compared to chemotherapy (8.2 vs 5.4 months) and  higher DCR 
(92% vs 76%) in a combined subgroup analysis of the phase III LUX-LUNG 3 and LUX-LUNG 
6 studies, including 81 patients who had CNS metastases (Table 1)  [98].  
The majority of patients with EGFR-mutant NSCLC, with initially good response to EGFR 
TKIs, acquires resistance to these drugs and develop CNS metastases, including leptomeningeal 
metastases (LM) [99, 100]. Several acquired resistance mechanisms, such as T790M secondary 
mutation [101, 102], MET amplification [103], and small cell transformation [104] have been 
reported. Pharmacokinetic failure due to insufficient penetration of standard-dose EGFR-TKIs 
is also regarded as a cause of CNS failure to EGFR-TKI [105]. High dose EGFR-TKIs has been 
considered as a reasonable therapeutic option for refractory CNS metastases after failure of 
standard-dose EGFR-TKIs, and several studies have suggested their effectiveness [87, 88, 106-
110]. Indeed, high-dose erlotinib (1,500 mg weekly) was associated with a partial control of 
CNS metastases and stable disease in 67% and 11% of patients, respectively, in a retrospective 
series of nine individuals with EGFR-mutant lung cancer (Table 1); the median time to 
progression of CNS metastases was 2.7 months (range, 0.8–14.5 months), and the median OS 
was 12 months (range, 2.5 months to outcome not reached) [88]. Despite the clinical benefit 
shown with high dose TKI in the above mentioned studies, which are mostly case series or case 
reports with low evidence grade, there is an unmet need in finding new targeted treatments, 
especially for patients who develop acquired resistance mechanisms. Third-generation 
8 
 
irreversible EGFR-TKIs such as rociletinib, WZ-4002, and osimertinib have been recently 
developed and act as mutant-selective agents against both T790M (most common resistance 
mutation to first-generation TKI for exon 19 positive tumours) and the initial EGFR mutations 
but not against wild-type EGFR. [80, 111-113]. Data from the TIGER-X phase 1-2 study were 
promising regarding the effect of rociletinib in EGFR mutated lung adenocarcinoma patients, 
but further development of this drug was prematurely stopped [114]. Osimertinib is now 
considered a standard therapy for patients who develop resistance to first-/second-line EGFR 
TKIs through T790M-mutation in exon 20 [80, 115, 116] and is also indicated as first-line 
treatment in treatment-naïve advanced NSCLC patients with sensitizing EGFR-mutant 
tumours. These third- generation TKIs have shown activity against CNS metastases in the 
second-line TKI setting [117, 118]. Osimertinib achieves higher CSF/brain-to-blood ratio in 
mouse models than gefitinib, erlotinib or afatinib [119-121]. Data from TIGER-X study 
regarding the effect of rociletinib on CNS metastases were presented in ECCO 2015, showing 
ORR up to 45% and DCR up to 75% in the CNS [122]. In a pooled analysis of two phase II 
single-arm studies with osimertinib in T790M-positive NSCLC patients (AURA extension and 
AURA2, N=50), an intracranial ORR of 54% was observed, together with a 12% CR and a 92% 
DCR in the CNS [121]. In the phase III AURA3 study, osimertinib was compared to 
platinum/pemetrexed in EGFR-mutated tumours which had progressed on first-/second-
generation EGFR TKIs (N= 419, n= 46 patients with measurable BM). In this trial, the CNS 
ORR to osimertinib was 70% vs 31% to chemotherapy. The median intracranial PFS was 11.7 
months with osimertinib and 5.6 months with platinum/pemetrexed [HR=0.32; 95% CI, 0.15 to 
0.69; P=0.004] [123]. A summary of clinical trials evaluating efficacy of EGFR TKIs in BM 
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1.4.3 ALK-targeted therapies: The EML4–ALK rearrangement is a genetic aberration that 
affects approximately 3–5% of all NSCLC, mainly younger, former light/no smoking history, 
and adenocarcinoma patients [124]. Of note, up to 30-70% of patients with ALK-positive lung 
cancer have been shown to develop brain metastasis [7, 8]. The ALK targeting agent crizotinib 
is the first approved agent for the treatment of ALK-positive NSCLC [125, 126]. The use of 
second-generation TKIs ceritinib, brigatinib and alectinib in the first- and second-line setting 
has shown similar efficacy both intracranially and extracranially, and seem to substantially 
reduce the cumulative risk of developing BM  [8, 127-134]. 
Despite reports indicating poor penetration of crizotinib into the CSF [135], patients treated 
with ALK-targeted agents have frequently shown clinical response in the brain [125, 131], 
suggesting a potential role for these agents in the treatment of brain metastasis. Updated results 
from the PROFILE 1014 study showed a higher intracranial DCR at 12 and 24 weeks after 
treatment initiation, a higher ORR and longer PFS with crizotinib versus chemotherapy in the 
subgroup of patients with treated BM before study enrolment [136]. A retrospective analysis of 
the PROFILE 1015 and PROFILE 1007 trials with second-line crizotinib in ALK-rearranged 
lung adenocarcinoma studied the efficacy of this drug in BM disease [137]. Of 888 patients 
enrolled in these trials, 31% had asymptomatic BM. The DCRs at 12 weeks in the previously 
untreated or treated BM cases were 56 % (95 % confidence interval (CI) 46–66) and 62 % (95 
% CI 54–70), respectively. ORRs in previously untreated or treated with radiotherapy were 18 
% (95 % CI 5–40) and 33 % (95 % CI 13–59), respectively. The intracranial duration of 
response (DOR) in previously treated or untreated patients with an overall response was 26.4 
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(95 % CI 6.1–59.3) and not reached (95 % CI 6.0–59.9), respectively. Systemic PFS was not 
affected by the presence or absence of BM at baseline. Crizotinib is a substrate for the ATP-
binding cassette (ABC) drug efflux transporters multidrug resistance protein 1 (also known as 
P-glycoprotein or ABC subfamily B member 1 [ABCG2]) and ABC subfamily G member 2 
(ABCG2; also known as breast cancer resistance protein), which provides a potential reason for 
wide variability and overall poor accumulation of the drug in the brain [135]. In support of this 
theory, ABCB1–/– and ABCG2–/– mice had a 25–70-fold higher brain concentration following 
oral administration of crizotinib compared with wild-type mice [135]. Similar results were 
obtained when crizotinib was administered along with elacridar, an inhibitor of these efflux 
pumps [138]. These preclinical data, together with clinical evidence of intracranial efficacy of 
crizotinib [136, 139-142], indicates the potential utility of this drug for the treatment of brain 
metastasis of ALK-positive lung cancer.  
In ASCEND-1 and -2 trials of ceritinib in ALK-rearranged lung adenocarcinoma, the 
intracranial DCR was 60.7% and 84.8% respectively, the overall intracranial RR was 35.7% 
and 39.4%, respectively, and median intracranial DOR 11.1 and 12.8 months, respectively, in 
patients who had previously received crizotinib [8, 130, 143]. ASCEND-3 trial has shown 
similar activity in ALK-rearranged lung adenocarcinoma patients with BM [144] (Table 2). 
These data were validated by the first-line study with ceritinib (ASCEND-4) which showed 
better IC ORR and PFS in ALK+ tumours in comparison with platinum-based chemotherapy 
(PFS by investigator assessment in BM patients: HR=0.58; 95% CI 0.36–0.92) [142]. Ceritinib 
has also shown activity in alectinib-pretreated patients with BM [145].  
A phase 1/2 trial evaluated the efficacy of alectinib in patients with crizotinib-resistant ALK-
rearranged NSCLC. In this trial, 11 out of 21 patients (52%) with CNS metastases at baseline 
achieved an ORR, and 5 out of 9 patients (56%) with measurable CNS lesions at baseline 
achieved a PR. Paired CSF and plasma samples of 5 patients showed measurable CSF 
concentrations of alectinib, and the drug showed promising activity even in patients with 
leptomeningeal dissemination [133]. In two phase 2 trials of alectinib in crizotinib-resistant 
ALK-rearranged lung adenocarcinoma the intracranial RR was 55.9% (34 patients with 
measurable CNS disease at baseline) [146] and 48% (69 patients with measurable CNS disease 
at baseline), respectively [134]. A pooled analysis of two of the above-mentioned single arm 
phase 2 studies with alectinib in crizotinib-resistant ALK-rearranged lung adenocarcinoma 
patients with CNS metastases included 50 patients (37%) with measurable CNS disease. 64% 
of these 50 patients had an OR (measured by independent review committee), DCR was 90% 
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and median DOR in CNS was 10.8 months. For all patients with CNS disease (both measurable 
and non-measurable CNS disease) the effect of alectinib was similar. ORR was 35.8% and 
58.5% in patients with or without previous CNS radiotherapy, respectively [147]. In the ALUR 
trial, ALK-positive patients that had progressed on crizotinib and platinum CT were 
randomized to receive alectinib or CT (pemetrexed or docetaxel). Patients with measurable 
baseline CNS disease (alectinib, n=24; CT, n=16) treated with alectinib had a significantly 
higher CNS ORR (54.2%) versus those who received CT (0%; P<0.001) [148]. The 
multinational phase III study ALEX comparing alectinib versus crizotinib in treatment-naïve 
ALK-rearranged patients established alectinib as a first-line treatment choice. In this trial, the 
rate of CNS response to crizotinib in patients with measurable CNS lesions at baseline was 50% 
compared to 81% with alectinib, resulting in a cause-specific HR of 0.16 (95%CI 0.10-0.28). 
The median duration of CNS response was 5.5 months (95%CI: 2.1-17.3) with crizotinib and 
17.3 months (95%CI: 14.8 to not estimable) with alectinib. Furthermore, the cause-specific HR 
for time to CNS progression was 0.18 for alectinib vs. crizotinib in patients with BM at baseline, 
and 0.14 for patients without baseline BM. These results indicate a reduction in the cumulative 
risk of developing BM in the alectinib arm [129]. This result is supported by the Japanese J-
ALEX trial which had a similar design as the ALEX trial, where HR for CNS progression or 
death was 0.16 (95%CI: 0.02-1.28) for patients with BM at baseline and 0.41 (95%CI: 0.17-
1.01) for patients without baseline BM for alectinib as compared to crizotinib [128].  
Brigatinib has shown similar activity in ALK-rearranged CNS metastasized lung 
adenocarcinoma patients in a phase I/II trial, with 53% ORR (15 patients with measurable CNS 
lesions) and 87% intracranial DCR [149]. For all patients with an intracranial response (n = 19), 
median duration of intracranial response was 18.9 months. Brigatinib is now an established 
first-line treatment for ALK-positive NSCLC patients. In the randomized phase 3 trial ALTA-
1L, brigatinib showed significantly superior PFS compared to crizotinib in treatment-naïve 
patients. This PFS benefit was consistent in subgroup analyses, including patients with BM.  
The estimated rate of 12-month survival without IC disease progression among patients with 
BM at baseline was 67% (95% CI, 47- 80) in the brigatinib group and 21% (95% CI, 6- 42) in 
the crizotinib group. The estimated rate of 12-month survival without IC disease progression in 
the intention-to-treat (ITT) population was 78% (95% CI, 68- 85) in the brigatinib group versus 
61% (95% CI, 50- 71) in the crizotinib group. The rate of survival without IC disease 
progression among patients with baseline BM was higher in patients with brigatinib than with 
crizotinib (HR= 0.27; 95% CI, 0.13- 0.54) and the rate of survival without IC disease 
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progression among patients in the ITT population was higher in the brigatinib group than in the 
crizotinib group (HR= 0.42; 95% CI, 0.24- 0.70). An exploratory competing-risks analysis of 
IC disease progression, systemic progression, and death in the ITT population showed that the 
cause-specific hazard ratio for time to progression of IC disease was 0.30 (95% CI, 0.15- 0.60) 
[127]. The results of ALTA-1L trial are similar to ALEX and J-ALEX trials regarding the 
reduction of cumulative risk of developing BM during the course of the disease.   
The novel second generation ALK-TKI ensartinib significantly prolonged progression-free 
survival over crizotinib with a favorable safety profile, in the global, phase 3, open-label, 
randomized eXalt 3 study. 290 patients with ALK- positive NSCLC who have received no prior 
ALK TKI and up to one prior chemotherapy regimen were randomized in this trial. The IC 
ORR was 64% with ensartinib versus 21% with crizotinib [150]. No robust clinical data for the 
efficacy of the third-generation TKI entrectinib in ALK-positive lung adenocarcinoma with BM 
are yet published. The third-generation ALK TKI lorlatinib has shown efficacy in BM with an 
ORR in target lesions reaching 60% in ALK- and ROS1-rearranged tumours [151]. 
Unpublished data from a phase 2 trial with lorlatinib in 57 heavily pretreated ALK-rearranged 
patients showed a promising IC ORR of 54% with IC DOR 12.4 months [152]. Lorlatinib 
showed an impressive IC ORR of 82% and IC CR of 71%, in patients with measurable BM in 
the global phase 3 randomized CROWN study. In this trial, lorlatinib was compared to 
crizotinib in treatment naïve patients with ALK-positive NSCLC, and showed a statistically 
significant and clinically meaningful improvement in PFS vs crizotinib. HR for time to 
intracranial progress was 0.07 (95% CI: 0.03-0.17) in favor of lorlatinib compared to crizotinib 
[153]. Results from larger ALK-positive BM cohorts regarding the IC efficacy of third-
generation TKIs are eagerly expected. A summary of clinical trials evaluating efficacy of ALK 
TKIs in NSCLC with BM is presented in Table 2. 
Table 2. Trials evaluating efficacy of ALK TKIs in NSCLC patients with BM. 
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1.4.4 Immunotherapy in NSCLC with BM: Currently, anti PD-(L)1 inhibitors such as 
nivolumab, pembrolizumab and atezolizumab, are approved for pre-treated advanced NSCLC 
[29,30,60,61]. Single agent pembrolizumab, with or without platinum-based chemotherapy, is 
currently approved as fist-line treatment for advanced NSCLC patients without EGFR/ALK 
molecular aberrations [62-65]. The quadruplet 
carboplatin/paclitaxel/bevacizumab/atezolizumab is another first-line approved regimen, with 
efficacy data also in the EGFR-/ALK-positive population [66].  
Patients with NSCLC and BM were underrepresented in most of these registration studies, 
where only asymptomatic cases were included. In the second-line setting, few patients with 
asymptomatic BM were included in the trials with PD-1 inhibitors nivolumab and 
pembrolizumab versus docetaxel. The small subgroup analyses evaluating these patients did 
not show any clinical benefit with immune checkpoint inhibitors (ICIs) compared to single 
agent docetaxel. The OAK trial, investigating the PD-L1 inhibitor atezolizumab, showed a 
longer OS compared to docetaxel in the subgroup of patients (85 out of 850) with asymptomatic 
BM (HR=0.54; 95% CI: 0.31-0.94) [154-157] (Table 2). In the KEYNOTE-024 trial, the 
subgroup of patients without BM at baseline (172 out of 305) had a better PFS with 
pembrolizumab versus chemotherapy (HR=0.50; 95% CI: 0.36–0.68) [158]. In the KEYNOTE-
407 trial comparing chemotherapy with or without pembrolizumab in the first-line setting of 
advanced squamous cell NSCLC, no subgroup analysis was presented for patients with 
asymptomatic BM at baseline (44 out of 559) [159]. A retrospective exploratory subgroup 
analysis of the KEYNOTE-189 trial (platinum/pemetrexed +/- pembrolizumab in the first-line 
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setting for advanced non-squamous NSCLC), presented at the 2019 annual American 
Association of Cancer Research (AACR) meeting, evaluated survival outcomes among patients 
with BM at baseline. 108 of 616 patients (17.5%) had treated and/or stable BM at baseline and 
received platinum/pemetrexed or platinum/pemetrexed plus pembrolizumab. The 
chemotherapy/ICI combination showed a longer OS in patients with BM (7.5 vs 19.2 months, 
HR 0.41, 95% CI, 0.24-0.67) and without BM (12.1 vs 22.4 months, HR 0.59, 95% CI, 0.46-
0.75). HR for PFS were also in favour of the chemotherapy/ICI combination treatment with an 
improvement of median PFS from 4.7 to 6.9 months (HR 0.42, 95% CI, 0.27-0.67) in patients 
with BM and an improvement from 4.9 to 9.2 months (HR 0.48, 95% CI, 0.39-0.59) without 
BM[160]. The combination treatment was well tolerated in patients with BM and no new safety 
signals were identified. The OS and PFS benefit of the chemotherapy/ICI combination observed 
in patients with BM was similar to that seen in the overall population, adding evidence to the 
role of this regimen in the first-line setting in this subgroup. 
Interim analysis of the non-randomised phase 2 study by Goldberg et al. evaluating 
pembrolizumab in small (5-20mm), asymptomatic BM was presented at ASCO 2018. Thirty-
nine patients (34 with PD-L1 positive and 5 with PD-L1 negative/unevaluable tumours) were 
treated with pembrolizumab. Pembrolizumab was given as first, second or later line of treatment 
in 30.8%, 35.9% and 33.3% of patients, respectively. In PD-L1 positive patients, IC ORR, IC 
PFS (among patients with response or SD in the BM) and median OS were 29.4% (95% CI 
15.1-47.5), 10.7 months (95% CI 6.6- not reached), and 8.9 months (95% CI 6.6-29.7 months), 
respectively. There were no IC responses in patients with PD-L1 negative or un-evaluable 
tumours [67]. 
A recently published retrospective analysis evaluated the efficacy of ICI in 1025 patients with 
NSCLC treated in 6 European centers [68]. Two hundred and fifty-five patients (14.3% were 
symptomatic) had BM at initiation of ICI therapy. With a median follow up of 15.8 months, 
there was no difference in ORR (20.6% vs 22.7%; P = .484) for patients with or without BM. 
IC ORR was 27.3%, and IC DCR was 60.3%. Median PFS was 1.7 months in patients with 
BM, compared to 2.1 months in patients without (P = .0009). The median OS was 8.6 vs. 11.4 
months for patients with and without brain metastases, respectively (P = .035). These results 
suggest that ICI is active in patients with BM and these patients should not be excluded from 
future clinical trials.  
A case series with 5 patients with NSCLC and asymptomatic BM treated with nivolumab 
showed 1 CR, 1 PR and 1 SD. IC and systemic responses were largely concordant and time to 
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response ranged between 5 and 9 weeks [161]. A retrospective study with 241 NSCLC patients 
with BM, treated with PD-(L)1 inhibitors, showed an IC ORR of 27.3% in the subgroup with 
active BM (new or growing, 40% of all BM patients). The IC ORR was higher in PD-L1+ 
tumours (35.7%) vs. PD-L1- tumours (11.1%). Overall (IC+EC) ORR was 22.7% in patients 
without BM versus 20.6% in patients with BM (p=0.484). Median (95% CI) PFS and OS in 
patients without vs. patients with BM were 2.1 (1.9-2.5) vs. 1.7 (1.5-2.1) months and 13 (9-16) 
vs. 9 (7-13) months, UHVSHFWLYHO\7KHXVHRIFRUWLFRVWHURLGV36DQGPRUHWKDQPHWDVWDWLF
sites were associated with worse PFS and OS in the multivariate analyses [162].  
Promising results with ICI in BM have been demonstrated using real world data. The nivolumab 
expanded access programme (EAP) in Italy enrolled 372 squamous NSCLC patients, of which 
38 had asymptomatic, controlled BM. The DCR in BM patients was 47.3% (1 CR, 6 PR and 11 
SD), compared to 47% in the overall population. Median PFS and OS in BM patients were 5.5 
and 6.5 months, respectively [163]. The Italian nivolumab EAP for non-squamous NSCLC 
showed similar results. In 409 patients out of 1588 (26%) with asymptomatic BM, nivolumab 
achieved a DCR of 40% (3 CR, 65 PR, 96 SD) and a median OS of 8.1 months (95% CI 6.2-
10.1), without increased toxicity [164]. An observational multicentre French study in 43 
NSCLC patients with BM showed an IC ORR of 9% [95% CI: 3–23%]) and EC ORR of 11% 
[95% CI: 4–26%] with nivolumab. The IC DCR was 51% (95% CI: 37–66%) and did not differ 
significantly from the EC DCR (47% [95% CI: 31–62%]) (p=0.43). Patients were heavily pre-
treated and median overall and IC PFS were 2.8 (95% CI: 1.8–5.3) and 3.9 (95% CI: 2.8–11.1) 
months, respectively. Median OS was 7.5 (95% CI: 5.6–not reached) months.  [165]. A 
retrospective series evaluating the impact of nivolumab in NSCLC patients with BM, presented 
at WCLC 2018, showed a similar IC ORR of 10.4%, with an overall ORR of 20.8%, and a 
median duration of response of 11.5 months. IC PFS and OS were 8 and 9 months, respectively 
[166]. In recent work by Kim et al., IC and EC responses to ICI in lung cancer with BM were 
compared. In 11 patients that achieved a PR or SD in the primary lung tumour, eight showed a 
progression in BM. Interestingly, PD-1+ tumour infiltrating lymphocytes (TILs) were 
significantly decreased in BM compared to primary lesions, possibly contributing to a lack of 
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1.4.5 Other clinically actionable mutations: New data has emerged the past few years for the 
treatment of NSCLC (lung adenocarcinoma specifically) with novel TKIs. ROS1 fusion 
oncogene is detected in 1-2% of lung adenocarcinoma patients [169] and drugs like crizotinib 
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and lorlatinib have shown clinical activity in small patient populations [170-172], but no  
published data exist regarding activity in the CNS, except for the above mentioned unpublished 
data for lorlatinib [151]. The combination of the BRAF inhibitor dabrafenib with the MEK 
inhibitor trametinib has shown clinical activity in pre-treated BRAF mutated patients (V600E, 
1-2% Ƞf lung adenocarcinoma patients) in a phase 2 trial [173], but no data from clinical trials 
exist regarding CNS activity. Our research group has recently published a case report on a 
patient with primary CNS metastatic BRAF mutated lung adenocarcinoma with complete 
intracranial response to BRAF/MEK inhibition [174]. Since dabrafenib has shown activity in 
brain metastatic melanoma [175], it is highly probable that the same activity is going to be 
observed in lung adenocarcinoma patients with CNS disease, but more data are needed from 
clinical trials where BRAF mutated BM lung cancer patients are included. Other therapies 
targeting HER-2 mutations or amplification, MET exon 14 skipping mutation or amplification, 
RET fusions, NTRK fusions and other oncogenic drivers are in early clinical trials with variable 
results [176]. Results regarding activity of these compounds in BM of NSCLC are eagerly 
expected. 
 
1.5 Cellular antioxidant response and carcinogenesis  
 The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is a vital 
component of cellular antioxidant response and its activation in cancer cells promotes cancer 
progression and metastasis [177-179]. In pancreatic cancer cells, NRF2 supports cell 
proliferation and metabolism through the regulation of cap-dependent and cap-independent 
mRNA translation [180]. A key study by DeNicola et al showed that NRF2 promoted K-
RASG12D-initiated pancreatic and lung tumorigenesis as well as proliferation in cancer cell 
lines and human pancreatic cancer tissue. Furthermore, KRASG12D, BRAFV619E, and c-
MYCERT2 oncogenic signaling was related to increased mRNA and protein levels of Nrf2 and 
its target genes [181]. The role of NRF2 expression is most probably mediated through the 
promotion of expression of certain genes that are vital for cell proliferation and metabolism, 
such as NOTCH1, NPNT, BMPR1A, IFG1, ITGB2, PDGFC, VEGFC, and JAG1 [180, 182, 
183]. A recently published trial from Taiwan showed that cytoplasmic NRF2 expression in 
early stage NSCLC was correlated with worse prognosis and worse response to cisplatin-
based chemotherapy after relapse [184]. In another trial done in early stage NSCLC patients, 
cytoplasmic NRF2 expression, as well as expression of its stabilizing protein DJ1, were 
independent prognostic factors for poorer OS [185]. Thioredoxin reductase 1 (TrxR1) is the 
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cytosolic isoenzyme of the three different TrxRs found in human cells. Its role in cancer 
biology is less clear since it may protect normal cells from carcinogenesis, but may also 
promote cancer progression [186]. 
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 2. Aims of the thesis 
 
The main purpose of this thesis is to identify clinical and molecular biomarkers for BM of 
NSCLC, as well as to explore the molecular diversity between CNS metastases and primary 
NSCLC. The aims of each paper are described below. 
Paper I. Paper I aimed to find prognostic factors that can influence OS in lung cancer patients 
with BM treated with WBRT, in order to identify which patients will live long enough to 
experience the palliative benefit of WBRT, regarding disease control in the CNS. 
Paper II. In this paper, gene expression analysis was carried out from formalin-fixed, paraffin-
embedded (FFPE) tissue sections of primary lung tumours and matched brain metastases. The 
aim was to identify potential patterns of gene downregulation or upregulation in the BM setting 
that could potentially explain the dismal prognosis of these patients, function as a diagnostic 
tool and potentially aid the development of new treatment strategies. 
Paper III. In this study the validity of Lung-molGPA index in an ALK-positive lung cancer 
cohort with BM was explored, and a new prognostic scoring system which can be easily 
applicable in clinical practice was proposed. 
Paper IV. The aim of the fourth study was to investigate whether high expression of NRF2 or 
TrxR1 in early stage NSCLC is predictive for relapse in CNS or other organs. We focused 











3. Patients, materials and methods 
 
3.1 Patient cohorts 
Paper I was a single institution cohort study including 280 brain metastasized lung cancer 
patients who received WBRT at Karolinska University Hospital from the first of January 2010 
until the first of January 2015. Information about Recursive Partitioning Analysis (RPA) and 
Graded Prognostic Assessment (GPA) scores, demographics, histopathological results and 
received oncological therapy were collected.  
For paper II, patients with lung cancer with surgically removed BM were identified from two 
cohorts. The first cohort consisted of 725 patients with early-stage NSCLC, who received 
surgical treatment from 1/1/1995 to 30/12/2010 at Akademiska University Hospital in Uppsala, 
Sweden. The second cohort was the same which was used in paper I, consisting of 280 patients 
who had received WBRT during the course of their disease. We analysed a total of 43 tissue 
samples for systematic mRNA expression; 13 primary tumours and 30 brain metastases. The 
material was obtained from 25 patients, of which 13 underwent surgery of the primary tumour. 
The paired samples were 26 (13 patients with both available lung and brain tissue samples). 
Paper III was a retrospective cohort study, where initially 106 patients with advanced ALK- 
positive NSCLC who were treated between January 2009 to November 2019 at Karolinska 
University Hospital in Stockholm, Sweden were reviewed. 54 patients were diagnosed with BM 
and 44 patients received ALK-TKI as first-line therapy after BM diagnosis. The latter patient 
group was included in our analyses. We collected demographic data, information about given 
oncological therapy, histopathology and physicians´ evaluations of performance status before 
receiving ALK TKI for brain metastatic disease. 
Paper IV was a retrospective cohort study, consisting of 304 patients with surgically removed 
NSCLC. Patients received surgical treatment from 1/1/2006 to 30/12/2010 at Akademiska 
University Hospital in Uppsala, Sweden. Demographic data were collected retrospectively. We 
collected information about physician´s evaluation of performance status (PS) at the time of 
diagnosis, age at diagnosis, histology, relapse site, surgical stage of disease, smoking status and 
gender. The tissue micro array (TMA) cohort was based on diagnostic tissue from NSCLC 
patients operated at the Akademiska University Hospital in Uppsala between 1995 and 2010, 
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from the same cohort that was used in paper II. 258 patients were included in the final analysis 
due to missing data regarding tumour relapse. 
All studies have received ethical approval by the institutional review board/ethical committee 
in Stockholm (registration numbers: 2016/944-31/1, 2019-03658) and the ethical committee in 
Uppsala (registration numbers: 2006/325, 2012/532). Additional approvals by Stockholm 
Biobank (Bbk01605) and Uppsala Biobank (BbA-827-2018-058) were received.  
 
3.2 RPA, GPA and Lung-molGPA classifications 
We divided patients in RPA classes and GPA groups according to age, control status of primary 
tumour, KPS, number of BM and presence of extracranial disease. All patients in paper III were 
ALK positive and this was used in Lung-molGPA calculation. In paper I, brain MRI with 
contrast was performed in 85% of the patients. The rest of the patients (15%) had only CT- 
verified metastases, but all of these patients had >8 BM, therefore not influencing GPA scoring. 
In the same paper patients were divided into three GPA groups; group 0 (0-1 points), group 1 
(1.5-2.5 points) and group 2 (3-4 points), where group 0 was the worst prognostic group and 
group 2 the best prognostic group. In paper 2, brain MRI was available for all patients and GPA 
classification was done as described above for paper I. Brain MRI with contrast was performed 
in 68% of the patients in paper III and the rest of the patients (32%) had CT- verified metastases. 
However, all of the patients with CT-verified metastases had >4 BM, therefore not influencing 
the GPA scoring. Patients were divided into four Lung-molGPA groups; group 1 (0-1.0 points), 
group 2 (1.5-2.0 points) group 3 (2.5-3.0) and group 4 (3.5-4.0 points). In the same paper, 
patients were divided into four GPA (DS-GPA) groups; group 1 (0-1.0 points), group 2 (1.5-
2.5 points), group 3 (3.0) and group 4 (3.5-4.0 points). Group 1 was the worst prognostic group 
and group 4 the best prognostic group in both Lung-molGPA and DS-GPA (Table 4). Presence 
of extracranial disease was confirmed with CT scan of the thorax and abdomen in all patients 







Table 4. RPA, GPA (=DS-GPA) and Lung-mol GPA classifications 
RPA class                Class 1 
 
          Class 2 
 
          Class 3 
 Age < 65 years, KPS 
70, primary tumour 
under control, no 
extracranial 
metastases 












Age, y >60              50-59 <50 
KPS <70 70-80 90-100 
Number of BM >3 2-3                  1 












Age, y t70                <70  
KPS <70 70-80 90-100 
Number of BM >4 1-4                   
ECM Yes                 No 
Gene Status EGFR neg/unk and 
ALK neg/unk 
  
EGFR or ALK pos 
ECM: Extracranial Metastases, KPS: Karnofsky Performance Status, EGFR: Epidermal Growth Factor 
receptor, ALK: Anaplastic lymphoma kinase, neg: negative, unk: unknown 
 
3.3 RWD analysis and outcomes of patients 
A major concern in modern oncology is the external validity of the results from large 
randomized control trials (RCTs). The patients that are included in these RCTs are generally 
younger, with better PS and without comorbidities, something which rarely is the case in the 
clinical praxis [187, 188]. The purpose with real world data analysis (RWD) is to collect data 
and analyse the patients outcome in a real world setting, thus helping regulatory decision 
making and guiding clinicians in their daily praxis [189]. 
The papers in this thesis represent RWD analyses. This is the reason for the different GPA 
scoring between papers I-III, due to the low number of patients in the best prognostic group. In 
the clinical praxis, brain metastatic NSCLC patients with lower GPA score and RPA class 2 or 
3 are more common. The internal validity of RWD can be questioned, since information and 
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selection bias are unfortunately quite common. Missing data for some analyses was a problem 
in paper I, III and IV. The selection of some patients depending on the patient cohort used for 
the analyses is another limitation. Patients with worse prognosis are included in the WBRT 
cohort compared to patients with early stage disease in the surgical cohort. Despite these 
limitations which are known and cannot be avoided, RWD analyses play an important role in 
modern oncology and can assist clinicians regarding decision making. 
 
3.4 Immunohistochemistry/TMAs 
Immunohistochemistry (IHC) was conducted in tissue microarrays (TMA) from surgically 
removed lung tumours. Haematoxylin-eosin stained slides were reviewed by two pathologists 
and tumour areas to be included in the TMA were marked. No major discrepancies regarding 
IHC scoring between the two pathologists were observed. The TMA was constructed using a 
manual tissue arrayer (MTA-1, Beecher Instruments, Sun Prairie, CA) [190, 191]. All 
tumours were included in duplicates (2 x 1 mm tissue cores). 4 micrometer sections were cut 
from the TMA blocks, mounted on adhesive slides and baked in 60°C for 45 min. TMA 
blocks were successfully constructed for all 304 patients, but we could include only 258 in 
our analysis due to missing clinical data regarding tumour relapse. NRF2 and TrxR1 
expression was measured in cancer cells in the whole tissue, in the tumour area and in 
surrounding stroma separately. Cancer cells were defined as epithelial cells that expressed 
cytokeratin (CK+). The epithelial density was measured with CK expression in the whole 
tissue, tumour and stroma.  
 
3.5 Gene expression analyses 
Formalin-fixed, paraffin-embedded (FFPE) tissue sections of primary tumours and matched 
brain metastases were used for total RNA isolation, using RNeasy FFPE kit (Qiagen, Hilden, 
Germany). Tissue sections of 4 X 4 µm were used. RNA quantity and quality were assessed 
using RNA Screen Tapes on a 2200 TapeStation system (Agilent, Santa Clara, CA, USA) 
through the documentation of RNA integrity number curves.  
An nCounter FLEX™ Analysis System (nanoString, Seattle, WA, USA) using the nCounter® 
PanCancer Immune Profiling gene expression panel (nanoString Technologies Inc.) was used 
for the measurement of systematic mRNA expression. This panel covers 770 human mRNAs 
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associated  to  tumour-   and   immunity-related   pathways. A minimum input of 150 ng of 
total RNA was used for each sample. Fluorescentl colour-coded reporter probes and biotin-
labelled capture probes were hybridized to the mRNA on a thermal cycler overnight and 
automatically processed and loaded to the nanoString provided sample cartridge in the 
nCounter Prep Station. 
 
3.6 Statistical analysis 
For the characterization of the cohorts in all papers descriptive statistical methods were used. 
The normally distributed variables were presented as mean ± standard deviation (SD), while 
non-normally distributed variables are presented as median (interquartile range, IQR). The 
normality of all continuous variables was assessed by skewness and kurtosis. Protein 
expressions in paper IV were also tested with receiver operating characteristics (ROC) curves 
in order to find an optimal cut-off value. Kaplan–Meier curves were plotted to determine OS 
from different time points until death depending on the trial design of each paper. Patients 
who were alive at the time of data collection were treated as censored observations during the 
analysis. Curves were compared with the log-rank test. Subgroup OS analysis were performed 
when needed. In paper I subgroup OS analysis was stratified by RPA class. 
Predictors of OS were identified by Cox regression analyses. Univariate Cox regression 
analyses were undertaken in all papers including different variables depending on the 
respective trial design. The results from the univariate analysis with a significant p value, as 
well as variables considered clinically significant guided the selection of variables for the 
multivariate Cox regression analysis. In paper I, non-significant variables were removed from 
the model by stepwise backward selection and the multivariate analysis was done separately 
for RPA class and GPA class, due to overlapping.  
In paper II, mRNA expression normalization, hierarchical clustering, scatter plots, fold-
changes and statistical ranking of differentially expressed genes, along with FDR corrected p-
values, were performed using the nanoString nSolver analysis software (nanoString 
Technologies Inc.). mRNA raw expression counts were normalized to the top 100 genes and 
not to housekeeping genes. Hierarchical clustering was performed using Euclidean distance 
with average linkage. Normalized expression values of the top twelve differentially expressed 
mRNAs were extracted from all samples. Scatter plots and curves displaying ROCs along 
with values for area under curve (AUC) were acquired using Graphpad Prism 8. All 
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differentially expressed genes were subjected to KEGG term analysis, including calculation of 
Benjamini-Hochberg corrected p-values, through the miRWalk 3.0 software. Visualization of 
KEGG gene interaction networks was performed through the Net NetworkAnalyst 3.0 
software. Specifically, the node network was visualized through the layout settings “Force 
Atlas” and “Reduce Overlap”. 
For the calculation of our new prognostic score in paper III, ALK-Brain Prognostic Index 
(BPI), maximum score of 1.0 was given to factors with larger effect estimates, while 
maximum score of 0.5 to smaller effect estimates. C-statistics were implemented and a 
bootstrap validation with 1000 samples was performed. The mean C-statistic over the 
bootstrap samples was used as a measure of model performance, which also was statistically 
compared between the prognostic scores. The Kaplan–Meier approach with the log-rank test 
was then used to compare overall survival between the groups within the prognostic scores. 
The primary outcome was relative risk for relapse in CNS or other organ after surgery in 
paper IV and it was calculated by binary logistic regression. Odds ratios (OR) with 95% 
confidence intervals (CI) were calculated in univariate and multivariate regression analyses. 
Univariate logistic regression analyses were undertaken with NRF2 expression in cytokeratin 
positive (CK+) cells in different TMA compartments, TrxR1 expression in CK+ cells in 
different TMA compartments, and other clinically important parameters as independent 
variables. The variables that were found to be significant in predicting the risk for relapse, as 
well as variables that were deemed to be clinically significant predictors for the risk of relapse 
were included in the multivariate regression models. Fisher’s exact test was also implemented 
in order to test the correlation between tumour relapse and protein expression (high versus 
low).  
All statistical analyzes were done with SPSS versions 23 and 25 (IBM Corp, Armonk, NY, 








4. Results and discussion 
 
4.1 Prognostic factors affecting survival after whole brain radiotherapy in patients with 
brain metastasized lung cancer (paper I) 
In this single cohort RWD analysis 280 patients who received WBRT for brain metastatic 
lung cancer were included. 54.7% of patients died in the first 3 months after the start of 
WBRT. Pairwise log rank testing showed statistically significant differences in OS with p< 
.0001 between RPA classes 1–3 and 2–3 as well as GPA groups 0–1. The best prognostic 
GPA group 2 had a very low number of patients, something which influenced the results of all 
statistical analyses. A statistically significant longer OS was observed for patients <70 years 
(p< .0001). Subgroup OS analyses were performed for RPA classes taking into account GPA 
groups. The most interesting finding was in RPA class 2 subgroup (n= 165), where a 
statistically significant OS difference was observed between GPA group 0 (79 patients) and 
GPA group 1 (78 patients) with p= .004. 
Univariate survival analysis showed that age (both continuous and dichotomous variable with 
70 years as cutoff), open surgery in CNS before salvage WBRT, RPA class and GPA class 
group had a statistically significant impact on OS. In the multivariate analysis including RPA 
class, we found age and RPA class to be independent prognostic factors. In the multivariate 
analysis including GPA class, the independent prognostic factors were CNS surgery before 
salvage WBRT, age, symptomatic CNS disease and GPA group. A multivariate Cox 
regression analysis was also performed in RPA subgroup 2 (n= 165), which showed that age, 
CNS surgery before salvage WBRT and GPA group (1 vs. 0) were independent prognostic 
factors for OS. 
In order to further explore the heterogeneity in RPA class 2 subgroup, we performed a 
Kaplan–Meier OS analysis taking into account the different age and GPA groups. We divided 
the combined groups as described below; Group A (‘intermediate group’): age 70 and GPA 
group 0 [41/165], group B (‘good group’): age 70 and GPA group 1 or 2 [66/ 165], group C 
(‘intermediate group’): age >70 and GPA group 1 or 2 [20/165] and group D (‘bad group’): 
age >70 and GPA group 0 [38/165]. The pairwise log rank test showed a statistically 
significant difference in OS between groups A and D, as well as B and D. The median OS in 
days was 193 [95% CI: 147–239] (B group), 118 [95% CI: 55–181] (A group), 90 [95% CI: 
18–162] (C group) and 89 [95% CI: 51–127] (D group). 
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In the majority of the existing prognostic scoring systems for BM patients receiving cranial 
irradiation there are considerable drawbacks, mainly caused by the limited number of patients 
studied and the heterogeneity regarding the kind of radiotherapy used (WBRT or SRS) [15-
20]. In this real life cohort study, RPA and disease specific GPA were used, since they are the 
most practical, most validated and most used scoring systems for patients with BM from solid 
tumours [22]. The median OS found in RPA classes and GPA groups in our cohort are similar 
to those reported in the literature [13, 21, 22, 192]. The exception was GPA group 2 (GPA 
score 3-4) where we found a slightly worse OS than group 1, due to the low number of 
patients in group 2 (n=13).  
RPA classification has received criticism since it depends mostly on PS, and due to 
heterogeneity regarding prognosis mostly in RPA class 2 [15, 193]. In our cohort median OS 
for RPA class 3 was 41 days (95% CI 35-49 days), something which supports the omission of 
WBRT in this patient group. Median OS was 324 days (95% CI: 197-451 days) for RPA class 
1 patients, to whom WBRT should be given if clinically indicated. It is of major clinical interest 
to find a way to identify which patients should receive WBRT in the heterogeneous RPA 2 
class. WBRT has a palliative effect regarding CNS disease control, but not any proven OS 
benefit. Therefore, it is important to identify which patients will live long enough to overcome 
the early toxicity related to WBRT and experience its palliative benefit [49, 194]. We found 
that age over 70 years and GPA score can help choosing the right patient to receive WBRT in 
the heterogeneous RPA 2 subgroup. In the intermediate prognostic groups of RPA 2 patients, 
ZLWKHLWKHUDJH\HDUVDQG*3$SRLQWVRUDJH!DQG*3$SRLQWVDJHVHHPV
to be a stronger prognostic factor for OS compared to GPA. This real life cohort study showed 
that WBRT should be considered in a larger proportion of BM NSCLC patients compared to 
QUARTZ trial results, where all patients older than 65 years (not RPA class 1) do not seem to 
derive any benefit from WBRT [32]. 
The major limitations of this paper are its retrospective nature and the small number of patients 
in some subgroup analyses, making it prone to selection bias. A large number of patients died 
early after the completion of WBRT, something which constitutes the selection of “healthier” 
patients less likely. The majority of the subgroup analyses done in this paper had a relatively 
large number of patients, and in the cases where the number was low, no conclusion can be 
drawn. The recommendations from our study results regarding the correct use of WBRT is 




4.2 An immune gene expression signature distinguishes central nervous system metastases 
from primary tumours in non-small-cell lung cancer (paper II) 
In paper II, we identified patients with lung cancer with surgically removed BM from two 
cohorts. The first cohort consisted of 725 patients with surgically removed NSCLC and the 
second of 280 patients who had received whole brain radiotherapy during the course of their 
disease (i.e. the cohort used in paper I). From these 1005 patients who were screened, a total 
of 43 tissue samples was available for systematic mRNA expression; 13 primary tumours and 
30 brain metastases. This material was obtained from 25 patients, of which 13 underwent 
surgery of the primary tumour. The paired samples were 26 (13 patients with both available 
lung and brain tissue samples).  
Tissue samples were divided into two groups, primary and CNS metastasis, and subjected to 
mRNA array analysis using the nanoString Pan-Cancer Immune Oncology panel followed by 
ranking of transcripts with differential expression between the groups. mRNA expression 
between these groups was significantly altered (FDR corrected p-value <0.05) in 208 mRNAs 
(of totally 770). All differentially expressed transcripts displayed decreased expression in 
brain metastases compared to primary tumours, albeit with a large variation in relative fold-
changes (1.43- 96.70). Brain metastases clustered in a distinct manner compared to primary 
tumours regarding the fraction of differentially expressed genes. This pattern was 
substantiated when only including genes with a corrected p-value of <0.01, or when 
specifically selecting the top twelve most differentially expressed genes. Additionally, the 
mRNA expression of all genes from patients which had available both a primary tumour and a 
brain metastasis sample was analyzed. The mRNA expression was largely decreased in the 
brain metastatic lesion compared with the primary tumour, irrespective of investigated patient.  
Top differentially expressed genes, CCL19 and CCL21, were substantially dampened in the 
brain metastatic lesion. Of the top twelve most differentially expressed mRNAs, seven 
belonged to the chemokine (CCL19, CCL21, CXCL9, CCL14, CCL18) or cytokine receptor 
families (IL2RB, IL21R). The additional five most differentially expressed transcripts were 
CD48, GZMA, ITGA4, RUNX3 and TPSAB1. The diagnostic performance of our top 
differentially expressed mRNAs was investigated by computing their ROC scores. The best 
performing individual transcripts were CCL19 and CCL21 with an AUC score of 0.9795 and 
0.9667, respectively. All top twelve differentially expressed transcripts scored an AUC >0.90, 
with four of them scoring an AUC >0.95 (CCL19, CCL21, IL2RB and TPSAB1). 
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Finally, an in silico pathway association of all transcripts being differentially expressed in 
brain metastatic lesions was performed by computing their KEGG term associations. 35 
KEGG terms had a highly significant p-value (p < 0.0001, Benjamini-Hochberg corrected). 
Of these KEGG terms, “Cytokine-cytokine receptor interaction” achieved the highest number 
(56) of differentially expressed transcripts, of which seven were found among the top twelve 
differentially expressed transcripts. This KEGG-term analysis on differentially expressed 
genes revealed a concomitant enrichment of multiple KEGG-terms associated with the 
immune system. 
In paper II, a unique gene downregulation pattern in the brain metastatic setting compared to 
primary lung cancer was identified. These genes either belong to the cytokine and chemokine 
receptor families or are otherwise involved in immune response and immune cell activation. 
A statistically significant downregulation of several genes encoding for checkpoint proteins, 
including PDCD1 (encoding the PD-1 protein), CTLA4, LAG3 and ICOS was observed 
[195]. The role of CCL19 and CCL21, the most differentially expressed genes in our study, is 
to recruit Tregs, CD4 T-helper and activated T-cells, monocyte-derived dendritic cells and B-
cells to the tumour microenvironment through interaction with the chemokine receptor CCR7, 
another differentially expressed gene in our study. 
 An excellent diagnostic performance was observed for 12 genes in the ROC curves which 
were implemented for the evaluation of the differential gene expression. This 12-gene 
signature clearly separated brain metastases from primary tumours and several clinical 
applications of this signature are possible in the future. These applications can be related to 
the diagnosis of brain metastatic NSCLC from solid biopsies, monitoring of patients during 
treatment (especially with immunotherapy) or the use of this diagnostic signature in liquid 
biopsies (plasma or cerebrospinal fluid) when tumour material is not available.  
One limitation of our study is that sequencing was not performed in order to identify relevant 
mutations and in a second step correlate mutations with gene expression. Furthermore, no 
specific analyses of the tumor microenvironment were performed. Nevertheless, this study is 
one of only two studies in literature up-to-date which have shown an immunosuppressive 
environment in the brain metastatic setting, when matched gene expression analyses from 
primary lung cancer and brain metastasis were compared [196]. The results from paper II may 
explain the low intracranial response rates and the limited efficacy of ICIs for patients with 
brain metastatic NSCLC. This may open up for new treatment strategies of brain metastases 
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in NSCLC where modulation of chemokine and cytokine signaling can be used to create an 
“immune-rich” tumour microenvironment optimized for a response to ICIs. 
 
4.3 ALK-Brain Prognostic Index - a Prognostic Tool for Patients with ALK-Rearranged 
Non-Small Cell Lung Cancer and Brain Metastases (paper III) 
Paper III aimed to explore the validity of the Lung-molGPA index, as well as the possibility 
to develop a new prognostic scoring system in ALK-positive lung cancer patients with BM. 
For this reason, 44 patients who received ALK-TKI as first-line therapy after BM diagnosis 
were included in the study, after a screening of 106 ALK positive patients. 
Univariate analysis of clinically important variables showed that primary brain metastastic 
disease (HR=0.17; 95% CI: 0.05-0.58), PS (HR= 0.32; 95% CI: 0.13-0.79) and sex 
(HR=0.40; 95% CI: 0.17-0.95) were prognostic factors for OS. All these variables proved to 
be statistically significant independent prognostic factors for OS in the multivariate analysis 
and were included in our prognostic score, ALK-Brain Prognostic Index (ALK-BPI). In the 
design of ALK-BPI, maximum score of 1.0 was given to variables with larger effect 
estimates, such as primary brain metastatic disease (HR= 0.14; 95% CI: 0.04-0.48), and 
maximum score of 0.5 to smaller effect estimates, such as PS <3 (HR=0.29; 95% CI: 0.11-
0.79) and female sex (HR=0.27; 95% CI: 0.11-0.67). Patients were divided into two 
prognostic groups; the good prognosis group (1.5-2.5 points) with a median OS of 65.7 
months (95% CI: 47.3-84.1) and the poor prognostic group (0-1.0 points) with a median OS 
of 22.7 months (95% CI: 14.8-30.5). 
The different prognostic scores included in our analyses, ALK-BPI, Lung-molGPA and DS-
GPA were compared initially with log-rank test which was 0.0068, 0.006 and 0.0619, 
respectively. The univariate analysis of the different prognostic scores showed that DS-GPA 
prognostic groups were not significant for OS, not all Lung-molGPA groups differed 
significantly, while there was a clear difference between the two prognostic groups in the 
ALK-BPI. A bootstrap analysis with 1000 bootstrap samples was further undertaken. The 
mean C-statistics of the different prognostic scores were 0.6354, 0.6772 and 0.6796 for the 
ALK-BPI, Lung-molGPA and DS-GPA, respectively, and when compared to each other with 
the p-value no significant difference was observed. 
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Prognostic scores for lung cancer patients with BM, such as RPA, GPA and DS-GPA, were 
initially calculated using patient data from clinical study cohorts and their external validity 
can therefore be questioned [12, 13, 23]. In Lung-molGPA, the number of ALK-positive 
patients included in the statistical analysis was not given and EGFR-mutation positive patients 
were calculated together with ALK-positive patients. Another major limitation of the Lung-
molGPA is that available treatment options for ALK-positive lung cancer patients were 
limited and considered obsolete in daily clinical praxis nowadays (patients diagnosed between 
2006 and 2014) [24]. The number of BM and presence of extracranial metastases were not 
significant prognostic factors for ALK-positive patients in our study, a result which is in 
concordance with the results from a Chinese study, which also failed to validate the Lung-
molGPA score [26].  
The major limitations of our study are its retrospective nature and the relatively small number 
of patients included. On the other hand, this is the first prognostic score calculated in a 
homogeneous ALK cohort receiving ALK-TKI as first-line treatment for brain metastatic 
disease. The RWD analysis of our study strengthens the external validity of ALK-BPI. The 
results of our study are closer to what observed in daily clinical practice, where the number of 
BM and presence of extracranial disease do not seem to influence OS when patients are 
treated with second generation ALK TKIs. The results of the Kaplan-Meier analyses 
discriminate the ALK-BPI groups in a better way compared to the other prognostic scores, 
and the results from the bootstrap analysis with 1000 samples failed to show any statistically 
significant difference between the different prognostic scores. DS-GPA performed worst in all 
analyses without any statistical significance in log-rank test or univariate analysis. 
The three variables (primary brain metastatic disease, sex and PS) which are used in ALK-
BPI, are easily calculated in the clinical setting without the need of radiological evaluations. 
This important feature, together with the fact that ALK-BPI has only two prognostic groups 
with a clear difference in OS between them, renders it an attractive prognostic tool. 
4.4 NRF2 expression in early stage NSCLC is predictive for relapse in CNS (paper IV) 
In paper IV, multiplex IHC staining was implemented in surgical biopsies from early stage 
NSCLC patients. NRF2 and TrxR1 expression was measured in cancer cells in the whole 
tissue, in the tumour area and in surrounding stroma separately. Cancer cells were defined as 
epithelial cells that expressed cytokeratin (CK+). The epithelial density was measured with 
CK expression in the whole tissue, tumour and stroma. The primary outcome was relative risk 
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for relapse in CNS or other organ after surgery and it was calculated by binary logistic 
regression. 
We had information about NRF2 and TrxR1 expression in the different TMA compartments 
for 304 patients. 258 were included in the final analysis due to missing data regarding tumour 
relapse. 56.6% of these 258 patients did not experience a relapse, while the most common 
relapse site was the thoracic cavity (22.9%). 16 patients had relapse in the CNS (6.2%). The 
expression of TrxR1 in CK+ cells in the different TMA compartments failed to show any 
statistically significant risk for relapse, relapse only in the CNS or relapse in other sites. The 
same analyses done for NRF2 expression showed a significantly higher risk for relapse in the 
CNS, which was observed in CK+ cells in the whole biopsy compartment, with an OR of 7.36 
(95% CI: 1.64- 33.06) and a chi-square p-value of 0.003. The OR for relapse in the CNS was 
3.08 (95% CI: 0.97- 9.81) for the NRF2 expression in CK+ cells in the tumour compartment, 
and 3.05 (95% CI: 0.96- 9.72) in the stroma compartment. Chi-square p-values for the 
abovementioned compartments were 0.068 and 0.069, respectively. NRF2 expression was not 
correlated with higher risk for relapse in general in the different CK+ TMA compartments. 
Despite not being significant in the univariate analysis, age, histology and stage were deemed 
to be clinically significant variables and were included in the multivariate analysis together 
with the CK+/NRF2+ expression in the whole tissue. The CK+/NRF2+ expression in the 
whole biopsy was an independent positive predictive factor for CNS relapse with an OR of 
8.00 (95% CI: 1.70- 37.60), whereas none of the other variables were statistically significant. 
The median value of NRF2 expression was initially tested as a cut-off to define high versus 
low expression, in order to have an unbiased first analysis. The distribution of NRF2 
expression in the CK+ cells in the whole biopsy compartment was not normally distributed 
with a skewness of 4.6 and kurtosis of 28.7. The ROC analysis failed to show another optimal 
cut-off value and the median IHC expression of NRF2 was decided to be the most optimal 
cut-off for our cohort. 
NRF2 expression in CK+ cells in the surgical biopsy was an independent prognostic factor 
with 8-fold higher odds regarding risk for relapse in the CNS in our cohort of early stage lung 
cancer patients. To our knowledge, this is the first study to report a predictive biomarker for 
CNS relapse in early stage lung cancer. NRF2 expression seems to play a more important role 
in cancer progression and metastasis. This role is most probably mediated through the 
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promotion of expression of certain genes that are vital for cell proliferation and metabolism 
[180, 182, 183]. A recently published trial from Taiwan showed that cytoplasmic NRF2 
expression in early stage NSCLC was correlated with worse prognosis and worse response to 
cisplatin-based chemotherapy after relapse [184]. In another trial done in early stage NSCLC 
patients, cytoplasmic NRF2 expression, as well as expression of its stabilizing protein DJ1, 
were independent prognostic factors for poorer OS [185]. In our study we have not evaluated 
the cytoplasmic expression of NRF2, albeit NRF2 expression in the different tumour 
compartments in different cell types did not influence OS. 
The major limitation of our study is its retrospective nature making it prone to selection bias. 
A certain risk of information bias regarding missing follow-up data about tumour relapse also 
exists. Information bias regarding IHC scoring cannot be avoided, albeit considered limited in 
our cohort due to the methodology used (see methods). Overfitting of data was avoided in the 
first step of our analyses by choosing median IHC expression value as a cut-off in order to 
define high versus low protein expression. Further statistical analyses with ROC curves and 
descriptive analysis of the IHC staining distribution did not reveal any other optimal cut-off 
value. This methodology renders the protein expression analysis as unbiased. The size of our 
cohort was large enough in order to perform the planned statistical analyses, even though the 
number of patients with CNS relapse was relatively small, something which is expected in a 
cohort of early stage NSCLC patients. The real-world nature of our study strengthens the 
external validity of our results. Nonetheless, these results should be validated in an external 











The results from paper I suggest that the selection of brain metastatic lung cancer patients who 
are candidates for WBRT could be done in two steps. RPA classification is a useful and practical 
prognostic tool for making a first step assessment. WBRT should be omitted for RPA class 3 
patients without further evaluation, whereas RPA class 1 patients should receive WBRT, if 
clinically indicated. The second step assessment is solely for RPA class 2 patients, where we 
VXJJHVWWKDWSDWLHQWVZLWKDJH\HDUVDQG*3$SRLQWVVKRXld be treated as RPA 1 
patients. WBRT should be omitted in RPA 2 patients with age > 70. In RPA 2 patients with age 
\HDUVDQG*3$< 1.5 points WBRT could be a reasonable option. 
In paper II, a unique gene downregulation pattern in brain metastatic NSCLC samples 
compared to primary tumours was identified, especially regarding genes related to immune 
response and immune cell activation. This finding may explain the lower intracranial efficacy 
of systemic therapy, especially immunotherapy, in NSCLC patients with BM, and opens up for 
new treatment strategies. Furthermore, a 12-gene signature with excellent diagnostic 
performance for brain metastatic NSCLC was identified. 
Paper III proposes the new ALK-BPI score as a prognostic tool that can easily be applied for 
ALK-positive lung cancer patients with BM in daily clinical practice, and that has at least the 
same, if not better, prognostic value compared with the Lung-molGPA. The ALK-BPI score 
should be validated in a larger cohort consisting of brain metastatic ALK-positive patients 
receiving ALK-TKI in the first-line setting. 
Paper IV is the first study to report a predictive biomarker for CNS relapse in early stage 
NSCLC and the first trial to report the correlation between NRF2 expression and risk for CNS 
relapse. The external validation of these results is needed. The results of our trial could alter 







6. Future perspectives  
Despite the major advances in the diagnosis, treatment and radiologic imaging of NSCLC 
patients during the past decades, there is still an unmet need in identifying clinical and 
molecular biomarkers that will aid clinicians in choosing tailored treatments in an 
individualized setting. This need is even more profound in NSCLC patients with BM, due to 
their dismal prognosis and the low IC efficacy of most existing systemic and local therapies 
[194].   
The results of paper I are important regarding the selection of NSCLC patients with BM who 
should receive WBRT. There is an abundance of prognostic scores for this category of 
patients, some of which have major limitations and have not been widely applicated in the 
clinical praxis, perhaps with the exception of RPA and GPA [14, 22]. In our RWD analysis, 
age over 70 years was an independent prognostic factor for OS after WBRT. This result is 
concordant with our institution´s experience regarding brain irradiation of elderly patients and 
also with published studies in elderly patients with primary CNS tumours [197, 198]. Age 
over 70 years and GPA score can help choosing the right patient to receive WBRT in the 
heterogeneous RPA 2 subgroup. This finding can help clinical decision making in this frail 
patient category, albeit new prognostic biomarkers are needed. The combination of molecular 
biomarkers with clinical prognostic scores could be the optimal strategy in future trials for 
NSCLC patients with BM. 
Paper II was focused on identifying potential patterns of gene downregulation or upregulation 
in the BM setting of NSCLC patients, something that could explain the dismal prognosis of this 
patient category, function as a diagnostic tool and constitute new treatment strategies. The effect 
of systemic therapies in the CNS is limited for NSCLC patients and new treatments as well as 
predictive biomarkers are eagerly needed [57-59, 158]. The registration trials evaluating single 
ICI for advanced NSCLC have included small numbers of asymptomatic BM patients and data 
from such subgroup analyses, as well as from retrospective series have shown limited activity 
of ICI in BM NSCLC [161, 163-166, 168]. The unique gene downregulation pattern in BM 
compared to primary tumors which was observed in our study may explain the low intracranial 
response rates and the limited efficacy of immune checkpoint inhibitors (ICI) for patients with 
BM NSCLC. Multiple genes encoding for immune checkpoint proteins displayed substantially 
dampened expression in the BM samples compared to primary tumour. This may open up for 
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new treatment strategies of BMs in NSCLC where modulation of chemokine and cytokine 
signaling can be used to create an “immune-rich” tumour microenvironment optimized for a 
response to ICIs. In order to achieve higher response rates in the CNS, new treatment strategies 
are needed. Combination treatments with two different ICIs, or ICI and other drugs influencing 
the immune microenvironment/immune cells in the CNS, seem to be a reasonable approach 
[199, 200]. Furthermore, the 12-gene signature for brain metastatic NSCLC which was 
identified in our study had an excellent diagnostic performance and will be subject for further 
validation studies in other patient cohorts. 
The ALK-BPI proposed in paper III is a new prognostic tool that can easily be applied for 
ALK-positive lung cancer patients with brain metastases in the daily clinical practice, and that 
has at least the same prognostic value as Lung-molGPA. The older prognostic scores for 
NSCLC patients with BM, described in paper I, are considered obsolete regarding ALK-
positive disease. Lung-molGPA included EGFR and ALK-positive patients in the same group, 
something which is a major disadvantage since these two molecular entities differ substantially. 
In addition to that, patients included in Lung-molGPA received oncologic treatment before the 
introduction of new generation TKIs, which are considered standard of care today. These 
observations underline the need for an updated prognostic score for ALK-positive NSCLC 
patients with BM. The validation of the ALK-BPI score in a larger cohort, consisting solely of 
brain metastatic ALK-positive patients receiving ALK-TKI in the first-line setting, is an 
ongoing project at our clinic. Clinically meaningful prognostic scores, such as ALK-BPI, can 
contribute to the identification of patients with poor prognosis and eventually lead to the 
development of new treatment strategies.  
There is a lack of predictive and prognostic biomarkers in early stage NSCLC. Paper IV is the 
first study to report a correlation between NRF2 expression and risk for CNS relapse in early 
stage NSCLC. The early detection of CNS relapse may prove to be of vital importance for this 
patient category. The detection of CNS relapse when patients are asymptomatic, something 
which is translated clinically into a much better PS, have less tumour burden in the CNS and 
perhaps no extracranial disease, will most probably lead to an OS benefit. This assumption is 
derived from the evidence regarding the prognosis of these patients, where surgery for single 
metastasis, better PS, lower number of CNS metastases and the absence of extracranial disease 
is associated with a longer OS [23, 194]. The follow-up strategy for patients that have higher 
risk for CNS relapse after surgery should include brain MRIs in regular intervals. Nonetheless, 
these results should be validated in an external cohort before they can be implicated clinically. 
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In conclusion, there is an unmet need regarding biomarker research for NSCLC patients with 
BM. All these patients should be included in randomized clinical trials, something which is 
unfortunately not a routine nowadays. The combination of clinical and preclinical biomarker 
research expertise is of vital importance in order to narrow the gap between these two research 
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